We are live on !
Find out more
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
(+1.6%)
Cap. Flow
+$169M
Cap. Flow % of AUM
Cap. Flow %
8.75%
Top 10 Holdings %
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
1.2
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Ensign Group
ENSG
|
+$104M |
| 2 |
Encompass Health
EHC
|
+$86.2M |
| 3 |
CareTrust REIT
CTRE
|
+$42.1M |
| 4 |
UnitedHealth
UNH
|
+$19M |
| 5 |
Insmed
INSM
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.9M |
| 2 |
Natera
NTRA
|
+$44.5M |
| 3 |
Healthpeak Properties
DOC
|
+$32.5M |
| 4 |
Avantor
AVTR
|
+$23.3M |
| 5 |
Qiagen
QGEN
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.53% |
| 2 | Real Estate | 5.59% |
| 3 | Miscellaneous | 4.84% |
| 4 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Tarsus Pharmaceuticals
TARS
$3.19B
| $3.51M | 0.18% |
+55,710
| New | +$3.56M |
2026 Q2
0 quarters
|
|
77
Alto Neuroscience
ANRO
$862M
| $3.39M | 0.18% |
128,286
+3,118
| +2% | +$72.1K |
2026 Q1
1 quarter
|
|
78
ARS Pharmaceuticals
SPRY
$401M
| $3.02M | 0.16% |
377,007
+240,772
| +177% | +$2.07M |
2025 Q3
3 quarters
|
|
79
InflaRx
IFRX
$230M
| $2.92M | 0.15% |
1,304,069
-454,504
| -26% | -$854K |
2023 Q2
12 quarters
|
|
80
Intuitive Surgical
ISRG
$160B
| $2.88M | 0.15% |
7,241
-3,878
| -35% | -$1.69M |
2025 Q3
3 quarters
|
|
81
Alector
ALEC
$204M
| $2.86M | 0.15% |
1,423,873
+72,767
| +5% | +$156K |
2024 Q1
9 quarters
|
|
82
PUT
Universal Health Services
UHS
$11B
| $2.8M | 0.15% |
18,800
+600
| +3% | +$97.5K |
2026 Q1
1 quarter
|
|
83
Vor Biopharma
VOR
$1.08B
| $2.76M | 0.14% |
+149,681
| New | +$2.26M |
2026 Q2
0 quarters
|
|
84
Design Therapeutics
DSGN
$641M
| $2.75M | 0.14% |
+190,000
| New | +$2.37M |
2026 Q2
0 quarters
|
|
85
Karyopharm Therapeutics
KPTI
$11.7M
| $2.7M | 0.14% |
276,174
| – | – |
2026 Q1
1 quarter
|
|
|
86
CALL
Qiagen
QGEN
$10.4B
| $2.66M | 0.14% |
68,100
-408,200
| -86% | -$15.2M |
2026 Q1
1 quarter
|
|
87
PMV Pharmaceuticals
PMVP
$67.9M
| $2.53M | 0.13% |
1,890,904
-457,456
| -19% | -$587K |
2026 Q1
1 quarter
|
|
88
Contineum Therapeutics
CTNM
$313M
| $2.43M | 0.13% |
148,017
+1,606
| +1% | +$21.1K |
2025 Q3
3 quarters
|
|
89
Evommune Inc
EVMN
$185M
| $2.32M | 0.12% |
174,460
+119,780
| +219% | +$2.78M |
2026 Q1
1 quarter
|
|
90
Amarin Corp
AMRN
$249M
| $2.32M | 0.12% |
145,296
-2,419
| -2% | -$35.7K |
2018 Q1
33 quarters
|
|
91
Spruce Biosciences
SPRB
$130M
| $2.16M | 0.11% |
+40,000
| New | +$2.24M |
2026 Q2
0 quarters
|
|
92
Repligen
RGEN
$11.2B
| $1.96M | 0.1% |
14,401
-106,384
| -88% | -$13.1M |
2026 Q1
1 quarter
|
|
93
Invivyd
IVVD
$181M
| $1.95M | 0.1% |
2,237,015
-39,334
| -2% | -$49.3K |
2025 Q3
3 quarters
|
|
94
ProQR Therapeutics
PRQR
$182M
| $1.9M | 0.1% |
+1,022,265
| New | +$1.68M |
2026 Q2
0 quarters
|
|
95
Grace Therapeutics
GRCE
$40.6M
| $1.75M | 0.09% |
772,900
+16,300
| +2% | +$45.1K |
2026 Q1
1 quarter
|
|
96
Anteris Technologies
AVR
$572M
| $1.64M | 0.08% |
166,229
-234,958
| -59% | -$1.79M |
2025 Q3
3 quarters
|
|
97
Vir Biotechnology
VIR
$1.79B
| $1.6M | 0.08% |
156,636
-93,364
| -37% | -$888K |
2026 Q1
1 quarter
|
|
98
Editas Medicine
EDIT
$369M
| $1.49M | 0.08% |
458,809
+167,890
| +58% | +$491K |
2025 Q4
2 quarters
|
|
99
Whitehawk Therapeutics
WHWK
$183M
| $1.39M | 0.07% |
303,306
-3,494
| -1% | -$14.5K |
2025 Q4
2 quarters
|
|
100
Bio-Techne
TECH
$11.4B
| $1.36M | 0.07% |
19,308
-106,588
| -85% | -$5.76M |
2022 Q4
14 quarters
|
|
Similar funds
Eversept Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.
On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.
- Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
- Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
- Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
- Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
- Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
- Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
- Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.